(MedPage Today) — SAN ANTONIO — More than 70% of patients with advanced triple-negative breast cancer (TNBC) responded to an investigational bispecific antibody targeting PD-L1 and VEGF-A plus chemotherapy, a preliminary study showed.
Overall…
Understanding the potential of CAR-T therapy in autoimmune disease treatment
Originally developed for aggressive blood cancers, CAR-T cell therapy is now being explored as a possible breakthrough treatment for autoimmune...






